BLAINJECTIONINJECTABLEPriority Review
Approved
May 2016
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
21
Data completeness
5/8 — Partial
Priority Review
TECENTRIQ (atezolizumab) by Roche is programmed death receptor-1-directed antibody interactions [moa]. Approved for programmed death receptor-1 blocking antibody [epc]. First approved in 2016.
Drug data last refreshed 3h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TECENTRIQ (atezolizumab) is a monoclonal antibody that blocks the Programmed Death Receptor-1 (PD-1) pathway, enabling the immune system to recognize and attack cancer cells. It is administered intravenously and is approved across multiple solid tumor indications including non-small cell lung cancer, triple-negative breast cancer, and urothelial carcinoma. The drug represents a cornerstone immunotherapy in Roche's oncology portfolio.
$0.029BPart D
PeakStable
~15% of PD-1 inhibitor market (estimated based on competitive spending ratio)
Peak lifecycle status indicates mature portfolio with established teams; commercial focus is on market share defense and combination indication expansion rather than aggressive growth.
Mechanism of Action
Programmed Death Receptor-1-directed Antibody Interactions
Pharmacologic Class:
Programmed Death Receptor-1 Blocking Antibody
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (21)
SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer
Started Oct 2026
32 enrolled
Advanced Lung Non-Small Cell CarcinomaMetastatic Lung Non-Small Cell CarcinomaRecurrent Lung Non-Small Cell Carcinoma+2 more
BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
Started Aug 2026
550 enrolled
Small Cell Lung Cancer Extensive StageSmall-cell Lung CancerSmall Cell Carcinoma+5 more
A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer
Started Jul 2026
36 enrolled
Extensive-stage Small-cell Lung Cancer
Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma
Started Jul 2026
12 enrolled
OsteosarcomaPulmonary Recurrence of Osteosarcoma
Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
Started May 2026
35 enrolled
Small Cell Lung Cancer ( SCLC )Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Worked on TECENTRIQ at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.